Introduction Stricture formation is a major complication of Crohn’s disease, affecting more than half of patients and often leading to obstruction, repeated hospitalizations, and need for surgery. Current therapies primarily target inflammation, but effective strategies to prevent fibrosis and stricturing remain limited.
Introduction
Stricture formation is a major complication of Crohn’s disease, affecting more than half of patients and often leading to obstruction, repeated hospitalizations, and need for surgery. Current therapies primarily target inflammation, but effective strategies to prevent fibrosis and stricturing remain limited. Statins, widely used for cardiovascular disease, have demonstrated anti-inflammatory and anti-fibrotic properties, raising interest in their potential role in modifying disease progression in Crohn’s disease.
Problem Statement
Despite advances in biologic therapies, there are no proven pharmacological interventions that effectively prevent fibrotic complications like strictures in Crohn’s disease.
Summary
This large, real-world study evaluated the impact of statin use on stricture development in Crohn’s disease using two independent US population databases. In both cohorts, statin use was consistently associated with a significant reduction in the risk of new-onset intestinal strictures—approximately 28–29% risk reduction over a follow-up of around 3.5–4 years.
The findings were robust across two large datasets and after propensity score matching, suggesting that the observed benefit is independent of confounding clinical variables and background IBD therapies.
Mechanistically, statins may exert beneficial effects by reducing chronic inflammation and inhibiting fibrogenesis, which are central drivers of stricture formation in Crohn’s disease.
Clinically, this study introduces the possibility of drug repurposing—using statins as a disease-modifying adjunct in Crohn’s disease to prevent long-term structural complications. However, given the observational design, prospective randomized trials are needed before routine clinical adoption.
Overall, this study highlights a promising, low-cost, and widely available strategy to potentially alter the natural history of Crohn’s disease by targeting fibrosis rather than inflammation alone.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.